Dexamethasone study shows promising results for treating COVID-19 patients
The New England Journal of Medicine last week released a study showing that the use of dexamethasone resulted in a lower, 28-day mortality rate among patients receiving invasive ventilation or oxygen.
The study indicated lower incidence of death among 2,104 patients treated with dexamethasone, compared to 4,321 patients receiving usual care. However, results showed very little impact in patients not receiving respiratory support.
The Food and Drug Administration also recently updated its COVID-19 treatment guidelines for corticosteroids, including dexamethasone. FDA said such drugs can be used for up to 10 days in patients requiring supplemental oxygen, but not with those who are mechanically ventilated or do not require supplemental oxygen.
Related News Articles
Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…